Merck & Co. Inc. (MRK)

89.91
0.06 0.07
NYSE : Health Technology
Prev Close 89.97
Open 90.17
Day Low/High 89.62 / 90.46
52 Wk Low/High 72.05 / 92.64
Volume 3.55M
Avg Volume 8.27M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 231.61B
EPS 2.30
P/E Ratio 42.71
Div & Yield 2.44 (2.48%)
Jim Cramer on Merck CEO Ken Frazier: Everyone Has a Right to Speak Their Mind

Jim Cramer on Merck CEO Ken Frazier: Everyone Has a Right to Speak Their Mind

Merck CEO Ken Frazier is leaving Trump's business council.

Cramer: FANG and the Lessons of History

Cramer: FANG and the Lessons of History

What a difference 2 years make -- or 17.

Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly

Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly

Merck vs. Eli Lilly.

Jim Cramer on Amazon, Tesla, Starbucks, Exxon, Chevron, American Airlines, Southwest Airlines, Merck and Tax Reform

Jim Cramer on Amazon, Tesla, Starbucks, Exxon, Chevron, American Airlines, Southwest Airlines, Merck and Tax Reform

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks.

Does Merck's Rally Have Legs?

Does Merck's Rally Have Legs?

MRK has shaped up on the charts.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

47 Quarterly Dividend Declared By Merck

47 Quarterly Dividend Declared By Merck

Merck , said today that its board of directors authorized a quarterly dividend of 47 cents

Cramer: Let Loose the Growth Hounds

Cramer: Let Loose the Growth Hounds

Day 2 of the selloff brings in an entirely new kind of buyer.

Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street

Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street

Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.

Merck Ready to Resume Long-Term Uptrend

Merck Ready to Resume Long-Term Uptrend

The price momentum and money flow indicators of the drug maker are in positive alignment.

Blue-Chip Breakouts: Intel, Boeing, and Merck Are Ready to Spring Higher in May

Blue-Chip Breakouts: Intel, Boeing, and Merck Are Ready to Spring Higher in May

These three big stocks are teetering on the edge of breakout territory to start the month.

The Good, the Bad and the Ugly (Late Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have I might be trading some of the earnings reports that will be released ...

Wake Up Wall Street: Trump Considers Breaking Up Big Banks

Wake Up Wall Street: Trump Considers Breaking Up Big Banks

Trump suggested he could split their consumer businesses from investment operations

2 'Swing for the Fences' Small Biotechs

2 'Swing for the Fences' Small Biotechs

Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.

2 'Swing for the Fences' Small Biotechs

2 'Swing for the Fences' Small Biotechs

Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Takeaways and Observations (Early Edition)

"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

'These companies are all assessing the Trump effect,' Cramer said.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

Today's Takeaways and Observations (Early Edition)

"I would describe today's market action as "benign." And that applies to almost every asset class." -- Kass Diary 104 trading sessions without a one percent drop in the indices. "Don't Think the Machines Could Turn to Selling? You've Forgotten 1987....

Health Care Putting in a Base

Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

In a 24-week trial of 22 patients, OncoSec saw a 41% response rate

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.